Please try another search
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Name | Age | Since | Title |
---|---|---|---|
Hans J. G. C. P. Schikan | 66 | 2019 | Independent Vice Chairman |
Robert Glassman | 62 | 2021 | Independent Non-Executive Director |
Berndt Axel Edvard Modig | 65 | 2015 | Co-Founder, CEO & Executive Director |
Viviane Monges | 61 | 2021 | Non-Executive Director |
David P. Meeker | 70 | 2021 | Independent Non-Executive Chair |
Elisabeth Bjork | 63 | 2021 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review